Abstract: Supertwist liquid-crystal displays (SLCDs) with outstanding properties are obtained if the nematic liquid-crystal mixtures used therein comprise at least one compound selected from the formulae 1A and 1B ##STR1## and at least one compound of the formula 1C ##STR2## in which R.sup.a is alkyl, alkoxy, alkenyl or alkenyloxy having 1 to 12 carbon atoms,R.sup.b is alkyl or alkoxy having 1 to 5 carbon atoms,Z is --COO--, --CH.sub.2 CH.sub.2 -- or a single bond, andL.sup.a, L.sup.b, L.sup.c, L.sup.d, L.sup.e, L.sup.f, L.sup.g, and L.sup.h in each case independently of one another are H or F,with the proviso that the 1,4-phenylene rings carry not more than 2 fluorine atoms per ring,R.sup.3 is an alkenyl group having 2 to 7 carbon atoms,R.sup.4 is R.sup.a or R.sup.3 andc is 0 or 1.

Abstract: This application relates to a method of treating a disease susceptible to treatment with a non-steroidal anti-inflammatory drug by administering to a patient once daily an effective amount of 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone.

Abstract: A class of substituted 7,8-ring fused 1,2,4-triazolo[4,3-b]pyridazine derivatives as shown in Formula I, possessing an optionally substituted cycloalkyl, phenyl or heteroaryl substituent at the 3-position and a substituted alkoxy moiety at the 6-position, are selective ligands for GABA.sub.A receptors, in particular having high affinity for the .alpha.2 and/or .alpha.3 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of pain.

Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.

Abstract: This invention relates to somatostatin agonist compounds which are potent with high selectivity toward the receptor subtype 2. Compounds of the formula: ##STR1## including pharmaceutically acceptable salts and hydrates thereof are disclosed. These compounds are useful in the treatment of diabetes, cancer, acromegaly, restenosis, depression, irritable bowel syndrome, pain and diabetic retinopathy. Many of the compounds are also orally active.

Abstract: The present invention is a method for identifying a patient at risk to developing fibrinogen receptor antagonist-induced thrombocytopenia which comprises incubating patient plasma with a GPIIb/IIIa receptor:GPIIb/IIIa receptor antagonist complex to form a GPIIb/IIIa receptor:GPIIb/IIIa receptor antagonist:plasma antibody complex, incubating the GPIIb/IIIa receptor:GPIIb/IIIa receptor antagonist:plasma antibody complex with a secondary anti-human detectable antibody to form a GPIIb/IIIa receptor:GPIIb/IIIa receptor antagonist:plasma antibody:secondary anti-human detectable antibody complex, and detecting the presence of the secondary anti-human detectable antibody in the GPIIb/IIIa receptor:GPIIb/IIIa receptor antagonist:plasma antibody:secondary anti-human detectable antibody complex.

Abstract: A process is described for the acclimation and enrichment of an activated sludge culture for the degradation of high concentrations of methanesulfonic acid, so as to render it non-toxic to the aquatic environment.

Abstract: The present invention relates to compounds of formula (I), ##STR1## wherein R.sup.1 represents halogen, hydroxy, C.sub.1-6 alkyl group optionally substituted by one or three fluorine atoms, C.sub.1-6 alkoxy group optionally substituted by one to three fluorine atoms, or C.sub.1-6 alkylthio optionally substituted by one to three fluorine atoms; R.sup.2 represents hydrogen, halogen, C.sub.1-6 alkyl or C.sub.1-6 alkoxy; or when R.sup.2 is adjacent to R.sup.1, they may be joined together such that there is formed a 5- or 6-membered saturated or unsaturated ring containing one or two oxygen atoms; R.sup.3 represents an optionally substituted 5- or 6-membered aromatic heterocyclic group containing 1, 2, 3 or 4 heteroatoms, selected from nitrogen, oxygen and sulphur; m is 0-3 and n is 0-3, with the proviso that the sum total of m+n is 2 or 3; p is zero or 1; q is 1 or 2; and when m is 1 and n is 1 or 2, the broken line represents an optional double bond; R.sup.4, R.sup.5, R.sup.6, R.sup.9 and R.sup.

Abstract: The present invention is directed toward radiolabeled farnesyl-protein transferase inhibitor compounds which are useful to label FPTase in assays, whether cell-based, tissue-based or in whole animal. The tracers can also be used in competitive binding assays to obtain information on the interaction of unlabeled FTIs with FPTase.

Abstract: The invention relates to a novel heat-stable form of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diph enylacetamide and to a process for the preparation and isolation of this compound in this novel form and to use for the production of medicaments which contain this compound and/or one of its physiologically acceptable salts.

Abstract: A process of synthesizing a compound of the formula 1: ##STR1## is described. A compound of the formula 2: ##STR2## is reacted with diphenylphosphinic chloride to activate the carboxylic acid group, and then reacted with methanesulfonyl chloride to produce a compound of formula 4: ##STR3## Compound 4 is then reacted with a group II metal sulfide source in water to produce a compound of formula 1.

Abstract: Cosmetic preparations for the care of aged, dry or irritated skin are prepared using a compound of the formula Ia or Ib ##STR1##

Abstract: The invention relates to fluorocyclohexane derivatives of the formula I ##STR1## in which R.sup.1, Z.sup.1, Z.sup.2, L.sup.1, L.sup.2, L.sup.3 and X are as defined as below:X is alkyl or alkoxy having 1 to 10 carbon atoms which is unsubstituted or substituted by halogen, alkenyl or alkenyloxy having 2 to 10 carbon atoms which is unsubstituted or substituted by --CN, --CF.sub.3 or --F, or is --CN, --F, --OCHF.sub.2, --OCF.sub.3, --OCHFCF.sub.3 or --OCF.sub.2 CF.sub.3,L.sup.1, L.sup.2 and L.sup.3 are each, independently of one another, H or F,R.sup.1 is H, an alkyl or alkenyl radical having 1-12 carbon atoms which is unsubstituted, monosubstituted by CN or CF.sub.3 or substituted by halogen, where one or more non-adjacent CH.sub.2 groups in these radicals may also, in each case independently of one another, be replaced by --O--, --S--, --CO--, --.diamond.--, --CO--O--, --O--CO-- or --O--CO--O--,Z.sup.1 and Z.sup.2 are each, independently of one another, --CO--O--, --O--CO--, --CH.sub.2 O--, --O--, --O--CH.sub.

Abstract: TN liquid-crystal displays and supertwist liquid-crystal displays (SLCDs) having very short response times and good steepnesses and angle dependencies are obtained by using nematic liquid-crystal mixtures which comprise at least one compound of formula IA ##STR1## and at least one compound of the formula IB ##STR2## in which R.sup.a, R.sup.b, R.sup.c, L and r are as defined herein.

Abstract: A dopant compound of the formula IR.sup.1 -(A.sup.1 -Z.sup.1).sub.n -A.sup.2 -W Iin which ##STR1## and R.sup.1, A.sup.1, A.sup.2, Z.sup.1 n, X and R.sup.a are as defined in claim 1, and to the use thereof as chiral dopants in liquid-crystalline media for electro-optical displays, and to electro-optical displays containing such media.

Abstract: This invention relates to somatostatin agonist compounds which are potent with high selectivity toward the receptor subtype 2. Compounds of the formula: ##STR1## including pharmaceutically acceptable salts and hydrates thereof are disclosed. These compounds are useful in the treatment of diabetes, cancer, acromegaly, restenosis, depression, irritable bowel syndrome, pain and diabetic retinopathy. Many of the compounds are also orally active.

Abstract: The invention relates to fluorocyclohexane derivatives of the formula I ##STR1## in which n, m, R.sup.1, X.sup.1, X.sup.2, Z.sup.1, Z.sup.2, A.sup.1 and Y are as defined above.

Abstract: A process for the preparation of a highly pure alkyl 2-cyanoacrylate, wherein alkyl has 1-10 C atoms, characterized in thata) formaldehyde is reacted with an alkyl cyanoacetate ester by means of a catalyst in a solvent mixture selected from the group comprising ethylacetate, diglyme, dichloroethane and benzene, yielding an oligo-(alkyl 2-cyanoacrylate);b) the product of (a) is separated in the form of a solid;c) the product of (b) is depolymerized under sulfur dioxide atmosphere free from other polymerization inhibitors to yield an alkyl 2-cyanoacrylate with a purity of 98-100%

Abstract: The invention encompasses the novel compound of formula (I) useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of formula (I).

Abstract: The full-length mouse .beta.3 integrin has been cloned and sequenced. A new form of .beta.3 integrin (.beta.3-trunc also been cloned and sequenced.